Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience
Vaccine, Volume 30, No. SUPPL. 2, Year 2012
Notification
URL copied to clipboard!
Description
A new Group A meningococcal (Men A) conjugate vaccine, MenAfriVac™, was prequalified by the World Health Organization (WHO) in June 2010. Because Burkina Faso has repeatedly suffered meningitis epidemics due to Group A Neisseria meningitidis special efforts were made to conduct a country-wide campaign with the new vaccine in late 2010 and before the onset of the next epidemic meningococcal disease season beginning in January 2011. In the ensuing five months (July-November 2010) the following challenges were successfully managed: (1) doing a large safety study and registering the new vaccine in Burkina Faso; (2) developing a comprehensive communication plan; (3) strengthening the surveillance system with particular attention to improving the capacity for real-time polymerase chain reaction (PCR) testing of spinal fluid specimens; (4) improving cold chain capacity and waste disposal; (5) developing and funding a sound campaign strategy; and (6) ensuring effective collaboration across all partners. Each of these issues required specific strategies that were managed through a WHO-led consortium that included all major partners (Ministry of Health/Burkina Faso, Serum Institute of India Ltd., UNICEF, Global Alliance for Vaccines and Immunization, Meningitis Vaccine Project, CDC/Atlanta, and the Norwegian Institute of Public Health/Oslo). Biweekly teleconferences that were led by WHO ensured that problems were identified in a timely fashion. The new meningococcal A conjugate vaccine was introduced on December 6, 2010, in a national ceremony led by His Excellency Blaise Compaore, the President of Burkina Faso. The ensuing 10-day national campaign was hugely successful, and over 11.4 million Burkinabes between the ages of 1 and 29 years (100% of target population) were vaccinated. African national immunization programs are capable of achieving very high coverage for a vaccine desired by the public, introduced in a well-organized campaign, and supported at the highest political level. The Burkina Faso success augurs well for further rollout of the Men A conjugate vaccine in meningitis belt countries. © 2012 Elsevier Ltd.
Authors & Co-Authors
Djingarey, Mamoudou Harouna
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
Barry, Rodrigue
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
Bonkoungou, Mete
Burkina Faso, Fada N'gourma
Ministry of Health
Tiéndrebéogo, Sylvestre R.M.
Burkina Faso, Fada N'gourma
Ministry of Health
Sebgo, Rene
Burkina Faso, Fada N'gourma
Ministry of Health
Kandolo, Denis
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
Lingani, Clément
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
Préziosi, Marie Pierre
Switzerland, Geneva
Organisation Mondiale de la Santé
France, Ferney-voltaire
Path
Zuber, Patrick Louis F.
Switzerland, Geneva
Organisation Mondiale de la Santé
Perea, William A.
Switzerland, Geneva
Organisation Mondiale de la Santé
Hugonnet, Stèphane Alexandre Louis
Switzerland, Geneva
Organisation Mondiale de la Santé
Dellepiane de Rey Tolve, Nora
Switzerland, Geneva
Organisation Mondiale de la Santé
Tevi-Benissan, Carol
Switzerland, Geneva
Organisation Mondiale de la Santé
Clark, Thomas A.
United States, Atlanta
Centers for Disease Control and Prevention
Mayer, Leonard W.
United States, Atlanta
Centers for Disease Control and Prevention
Novak, Ryan T.
United States, Atlanta
Centers for Disease Control and Prevention
Messonier, Nancy E.
United States, Atlanta
Centers for Disease Control and Prevention
Berlier, Monique
France, Ferney-voltaire
Path
Toboe, Desire
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
Nshimirimana, Deo
Unknown Affiliation
Mihigo, Richard M.
Unknown Affiliation
Aguado, Maria Teresa
Switzerland, Geneva
Organisation Mondiale de la Santé
Diomandé, Fabien V.K.
Burkina Faso, Ouagadougou
World Health Organization Ouagadougou
United States, Atlanta
Centers for Disease Control and Prevention
Kristiansen, Paul Arne
Norway, Oslo
Folkehelseinstituttet
Caugant, Dominique A.
Norway, Oslo
Folkehelseinstituttet
LaForce, F. Marc
France, Ferney-voltaire
Path
Statistics
Citations: 102
Authors: 26
Affiliations: 6
Identifiers
Doi:
10.1016/j.vaccine.2011.12.073
ISSN:
0264410X
e-ISSN:
18732518
Research Areas
Health System And Policy
Maternal And Child Health
Study Design
Cross Sectional Study
Study Locations
Burkina Faso
Participants Gender
Male